RTW Biotech Opportunities Ltd
RTW Biotech Opportunities Ltd is a closed-end fund that invests in biotechnology companies, generating returns primarily through capital appreciation and dividend income.
Business. RTW Biotech Opportunities Ltd is a closed-end fund that invests in biotechnology companies, generating returns primarily through capital appreciation and dividend income.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
RTW Biotech Opportunities Ltd is a closed-end fund that invests in biotechnology companies, generating returns primarily through capital appreciation and dividend income.
RTW Biotech Opportunities Ltd maintains a strong liquidity position, with a liquidity_fpt of 0.19, indicating that its long-term debt is relatively low compared to its equity. The company's cash and equivalents amount to $5,986,180, which, while modest, supports its operational needs. The debt-to-equity ratio of 0.19 suggests a conservative capital structure, with total liabilities significantly lower than total equity.
The company's profitability is robust, with a return on equity (ROE) of 28.34% and a return on assets (ROA) of 22.94%. These figures are well above the industry median for closed-end funds, indicating that RTW Biotech Opportunities Ltd is effectively utilizing its equity and assets to generate returns. The net income of $245,192,680 is a strong indicator of the fund's performance in its investment strategy.
RTW Biotech Opportunities Ltd's revenue is concentrated in the biotechnology sector, with no disclosed geographic diversification. The fund's investment strategy is focused on biotechnology, which is a high-growth but volatile sector. This concentration may expose the fund to sector-specific risks, such as regulatory changes or market downturns in biotechnology.
The fund's growth trajectory is positive, with a strong net income and a high ROE. The outlook for the current fiscal year is optimistic, with a mean recommendation of 1.00 from analysts, indicating a strong buy. The fund's operating cash flow of $105,253,150 supports its ability to sustain and potentially grow its operations.
The risk assessment for RTW Biotech Opportunities Ltd indicates a medium liquidity risk and a low dilution risk. The fund's liquidity is supported by its cash and equivalents and a conservative debt structure. However, the risk assessment also notes that net cash is negative after subtracting total debt, which could be a concern if the fund faces unexpected liquidity needs.
Recent events and filings for RTW Biotech Opportunities Ltd have not indicated any significant changes in the fund's strategy or operations. The fund's management has not disclosed any major new investments or divestitures in the latest filings. The fund's performance and strategy remain consistent with its stated objectives.
- RTW Biotech Opportunities Ltd has a strong return on equity (28.34%) and return on assets (22.94%), indicating effective use of capital.
- The fund maintains a conservative capital structure with a debt-to-equity ratio of 0.19.
- The fund's liquidity is supported by cash and equivalents of $5,986,180 and a low dilution risk.
- The fund's growth trajectory is positive, with a mean recommendation of 1.00 from analysts.
- The fund's revenue is concentrated in the biotechnology sector, which may expose it to sector-specific risks.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- RTW Biotech Opportunities Ltd Market data — financials · 2026-05-29
- RTW Biotech Opportunities Ltd Market data — analyst estimates · 2026-05-29